Hence the selection criteria for study entry focussed on those with a good performance status, low tumour burden and a normal serum albumin (a reliable prognostic factor), so that they were able to receive standard chemotherapy subsequently on disease progression. The gene discussed is ALB; the disease is neoplasm.